目的 探讨荷丹胶囊联合瑞舒伐他汀钙治疗老年高脂血症临床疗效。方法 选取2015年6月—2018年6月在航天中心医院老年病门诊进行治疗的100例高脂血症患者，根据用药不同分为治疗组（50例）和对照组（50例）。对照组口服瑞舒伐他汀钙片，10 mg/次，1次/d；治疗组在对照组治疗基础上口服荷丹胶囊，4粒/次，3次/d。两组均连续治疗8周。观察两组的临床疗效，比较两组治疗前后血脂指标、血清学指标和氧化应激指标的变化情况。结果 治疗后，对照组和治疗组的总有效率分别是82%、96%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）水平均显著下降，高密度脂蛋白胆固醇（HDL-C）水平均显著增高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组TC、TG、LDL-C水平低于对照组，但HDL-C水平高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组C反应蛋白（hs-CRP）、嗜酸性粒细胞阳离子蛋白（ECP）、成纤维细胞生长因子21（FGF-21）、摄食抑制因子-1（NSF-1）、瘦素（LEP）、白细胞介素-6（IL-6）、总氧化态（TOS）水平均较治疗前显著降低，而总抗氧化态（TAS）水平、对氧磷酶-1（PON1）表达均显著增高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组hs-CRP、ECP、FGF-21、NSF-1、LEP、IL-6、TOS水平明显低于对照组，而TAS、PON1水平明显高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 荷丹胶囊联合瑞舒伐他汀钙治疗老年高脂血症具有较好的临床疗效，可显著改善患者的血脂指标，降低血清炎性因子水平，改善机体氧化应激状态，具有较好的临床推广应用价值。

Objective To explore the clinical effect of Hedan Capsules combined with rosuvastatin calcium in treatment of senile hyperlipidemia. Methods 100 Patients with hyperlipidemia in Aerospace Center Hospital from June 2015 to June 2018 were divided into treatment group (50 cases) and control group (50 cases) according to different medication. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Hedan Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the changes of blood lipid indexes, serological indexes and oxidative stress indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 82% and 96%, and there were differences between two groups (P<0.05). After treatment, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and there were differences in the same group (P<0.05). After treatment, TC, TG, and LDL-C in the treatment group were lower than those in the control group, but HDL-C was higher than that in the control group, and there were differences between two groups (P<0.05). After treatment, hs-CRP, ECP, FGF-21, NSF-1, LEP, IL-6, and TOS in two groups were significantly decreased, but TAS, PON1 were significantly increased, and there were differences in the same group (P<0.05). After treatment, hs-CRP, ECP, FGF-21, NSF-1, LEP, IL-6, and TOS in the treatment group were lower than those in the control group, but TAS and PON1 was higher than that in the control group, and there were differences between two groups (P<0.05). Conclusion Hedan Capsules combined with rosuvastatin calcium has significant clinical effect in treatment of senile hyperlipidemia, and can significantly improve the blood lipid indexes, and also can reduce the level of serum inflammatory factors and improve the oxidative stress state, which has a certain clinical application value.